R&D Pipeline (As of July 2016) Underlined items indicate for changes from the previous announcement on May 11, 2016. 1. Global Development

(1) Regulatory decision *Compounds with "In-house" in this column include ones discovered by collaborative research. (The same applicable hereafter.) Code No. Dosage ClassificationTarget Disease Area / Phase Licensor* Remarks Generic Name Form Received a notification for end of procedure for the Muscarine M YM905 3 type 2 variation. The indication was not approved but receptor in pediatric patients Europe Oral In-house pediatric information was included in the label to antagonist of 5-18 years enable patent extension of 6 months.

(2) Filed Code No. Dosage Classification Target Disease Area / Phase Licensor Remarks Generic Name Form Metastatic castration-resistant MDV3100 Europe Filed Androgen receptor inhibitor prostate cancer Oral Medivation New formulation enzalutamide* (Mar. 2016) () * Withdrew the US sNDA in Feb. 2016 for tablet.

(3) Phase-lll / Phase-ll (1/4) Code No. Dosage Classification Target Disease Area / Phase Licensor Remarks Generic Name Form Non-metastatic castration-resistant US/Europe/Asia New indication prostate cancer Phase-III Prostate cancer in patients US/Europe/Asia with non-metastatic biochemical New indication Phase-III recurrence MDV3100 Metastatic hormone-sensitive US/Europe/Japan/Asia Androgen receptor inhibitor Oral Medivation New indication enzalutamide prostate cancer Phase-III US/Europe/Japan/Asia Triple-negative breast cancer New indication Phase-III Breast cancer US/Europe Phase-II New indication (ER/PgR positive, HER2 positive) Hepatocellular carcinoma US/Europe/Asia Phase-II New indication

29 (3) Phase-lll / Phase-ll (2/4) Code No. Dosage Classification Target Disease Area / Phase Licensor Remarks Generic Name Form

Cytomegalovirus reactivation US/Europe/Japan in hematopoietic cell Phase-III transplant recipients ASP0113 DNA vaccine Injection Vical (VCL-CB01) for cytomegalovirus Cytomegalovirus infection or reactivation US/Europe Phase-II in solid organ transplant recipients

YM905 Muscarine M receptor Neurogenic detrusor overactivity New indication 3 US/Europe Phase-III Oral In-house solifenacin antagonist in pediatric patients (pediatric)

EB178 Urinary frequency, Concomitant use of US/Europe/Asia solifenacin/ urinary incontinence or urgency Oral In-house solifenacin and mirabegron Phase-III mirabegron associated with overactive bladder

Infectious enteritis (bacterial target: Japan Phase-III Clostridium difficile ) fidaxomicin Macrocyclic antibiotic Oral Merck

Clostridium difficile infection New indication Europe Phase-III in pediatric patients (pediatric)

ASP015K Japan/Asia Phase-III JAK inhibitor Rheumatoid arthritis Oral In-house peficitinib US/Europe Phase-II

ASP1517 Anemia associated with chronic Europe Phase-III (FG-4592) HIF stabilizer kidney disease in patients Oral FibroGen Japan Phase-III roxadustat not on dialysis and on dialysis

30 (3) Phase-lll / Phase-ll (3/4) Code No. Dosage Classification Target Disease Area / Phase Licensor Remarks Generic Name Form US/Europe/Japan/Asia Acute myeloid leukemia Phase-III ASP2215 FLT3/AXL inhibitor Oral In-house gilteritinib US/Japan/Asia Non-small cell lung cancer Phase-I

Mutant-selective US/Europe/Japan/Asia ASP8273 Non-small cell lung cancer Oral In-house irreversible EGFR inhibitor Phase-III

YM178 Neurogenic detrusor overactivity New indication Beta 3 receptor agonist Europe Phase-III Oral In-house mirabegron in pediatric patients (pediatric)

YM311 Europe Phase-II HIF stabilizer Renal anemia Oral FibroGen (FG-2216) Japan Phase-I

Recurrence of focal segmental ASKP1240 Anti-CD40 Kyowa Hakko glomerulosclerosis in de novo US Phase-II Injection bleselumab monoclonal antibody Kirin kidney transplant recipients*

Europe/Japan Endometriosis Phase-II ASP1707 GnRH antagonist Oral In-house Rheumatoid arthritis Japan Phase-II

Diabetic nephropathy Europe Phase-II ASP8232 VAP-1 inhibitor Oral In-house Diabetic macular edema US Phase-II

* It was in the Phase-II stage in the US and Phase-I stage in Japan for prevention of organ transplant rejection. We have decided to focus on recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients in future development.

31 (3) Phase-lll / Phase-ll (4/4) Code No. Dosage Classification Target Disease Area / Phase Licensor Remarks Generic Name Form Painful diabetic peripheral US Phase-II neuropathy ASP3662 11beta-HSD1 inhibitor Oral In-house Alzheimer’s disease US Phase-I

Spinal muscular atrophy US Phase-II Fast skeletal CK-2127107 Oral Cytokinetics tropoinin activator Chronic obstructive pulmonary US Phase-II disease

ASP7962 TrkA inhibitior Osteoarthritis Europe Phase-II Oral In-house

In-house (ADC technology AGS-16C3F ADC targeting ENPP3 Renal cell carcinoma US/Europe Phase-II Injection in-licensed from Seattle Genetics) In-house Cell therapy Dry age-related macular (Astellas RPE cell (Retinal pigment degeneration, US Phase-II Injection Institute for program epithelium cell) Stargardt’s macular degeneration Regenerative Medicine)

32 2. Local Development: Japan

(1) Filed Code No. Dosage ClassificationTarget Disease Area / Phase Licensor Remarks Generic Name Form

Japan Filed ASP7374 Influenza vaccine Prophylaxis of seasonal influenza Injection UMN Pharma (May 2014)

Hyperphosphatemia ASP1585 in patients on dialysis Japan Filed (AMG 223) Amine-functional polymer Oral Amgen New formulation with chronic kidney disease (Sept. 2015) bixalomer (granule formulation)

ASP0456 Guanylate cyclase-C Irritable bowel syndrome Japan Filed Oral Ironwood linaclotide receptor agonist with constipation (Feb. 2016)

33 (2) Phase-lll / Phase-ll Code No. Dosage Classification Target Disease Area / Phase Licensor Remarks Generic Name Form FK949E Serotonin / Depressive episode New indication Japan Phase-III Oral AstraZeneca antagonist in bipolar disorders New formulation

ASP3550 Prostate cancer GnRH antagonist Japan Phase-III Injection Ferring New formulation degarelix (3-month formulation)

Amgen AMG 785 Anti-Sclerostin Osteoporosis Japan Phase-III Injection (co-development with romosozumab monoclonal antibody Amgen Astellas)

In-house ipragliflozin/ Fixed dose combination of Type 2 diabetes mellitus Japan Phase-III Oral (co-development with sitagliptin ipragliflozin and sitagliptin MSD and Kotobuki)

In-house ASP1941 SGLT2 inhibitor Type 1 diabetes mellitus Japan Phase-III Oral (co-development with New indication ipragliflozin Kotobuki)

ASP0456 Guanylate cyclase-C Chronic constipation Japan Phase-III Oral Ironwood New indication linaclotide receptor agonist

ASP7373 Influenza vaccine Prophylaxis of H5N1 influenza Japan Phase-II Injection UMN Pharma

Amgen AMG 103 Anti-CD19 BiTE Acute lymphoblastic leukemia Japan Phase-II Injection (co-development with blinatumomab Amgen Astellas)

34 3. Phase-l

Code No. Dosage Target Disease Licensor Generic Name Form ASG-22ME In-house Solid tumors, Urothelial cancer Injection enfortumab vedotin (co-development with Seattle Genetics) In-house ASG-15ME Urothelial cancer Injection (co-development with Seattle Genetics) ASP5878 Cancer Oral In-house In-house (ADC technology AGS67E Lymphoid Malignancies Injection in-licensed from Seattle Genetics) ASP2205 Stress urinary incontinence Oral In-house ASP5094 Rheumatoid arthritis Injection In-house ASP4132 Cancer Oral In-house ASP4345 Cognitive impairment associated with schizophrenia Oral In-house ASP6282 Underactive bladder Oral In-house ASP4070 Pollinosis caused by Japanese red cedar Injection Immunomic Therapeutics (JRC2-LAMP-vax) ASP0819 Fibromyalgia Oral In-house ASP8062 Fibromyalgia Oral In-house ASP7398 Nocturia Oral In-house ASP6294 Bladder pain syndrome / Interstitial cystitis Injection In-house ASP7266 Severe asthma Injection In-house ASP0892 Peanut allergy Injection Immunomic Therapeutics AGS62P1 Acute myeloid leukemia Injection In-house (ADC technology, EuCODE license from Ambrx)

4. Other items changed from the previous quarterly announcement on May 11, 2016 -Removed the description for new indication of Kiklin (bixalomer), which was approved in February 2016 in Japan.

35